Sugi Predict

Sugi Predict / Targets / DEGS1

DEGS1

Sphingolipid delta(4)-desaturase DES1 · O15121 · DEGS1 on Sugi Atlas →

21,201 patent compounds predicted against DEGS1, 15,139 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL851343 SCHEMBL851343 0.56 16/20
SCHEMBL752447 SCHEMBL752447 0.49 6/20
SCHEMBL179290 SCHEMBL179290 0.41 5/20
SCHEMBL715515 SCHEMBL715515 0.64 4/20
SCHEMBL899585 SCHEMBL899585 0.75 3/20
SCHEMBL900928 SCHEMBL900928 0.75 3/20
SCHEMBL778050 SCHEMBL778050 0.59 3/20
SCHEMBL777078 SCHEMBL777078 0.57 3/20
SCHEMBL125596 SCHEMBL125596 0.56 3/20
SCHEMBL716400 SCHEMBL716400 0.53 3/20
SCHEMBL805112 SCHEMBL805112 0.52 3/20
SCHEMBL890791 SCHEMBL890791 0.51 3/20
SCHEMBL679503 SCHEMBL679503 0.50 3/20
SCHEMBL557791 SCHEMBL557791 0.48 3/20
SCHEMBL115413 SCHEMBL115413 0.45 3/20
SCHEMBL116564 SCHEMBL116564 0.45 3/20
SCHEMBL118313 SCHEMBL118313 0.45 3/20
SCHEMBL164488 SCHEMBL164488 0.44 3/20
SCHEMBL198118 SCHEMBL198118 0.74 2/20
SCHEMBL199640 SCHEMBL199640 0.74 2/20

Clinical trials — most relevant to DEGS1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
D-Cycloserine for Serine Palmitoyltransferase Inhibition PHASE4COMPLETED
AntiCoagulants and COGnition PHASE4UNKNOWN
Hereditary Sensory Neuropathy Serine Trial PHASE2UNKNOWN
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis PHASE1/PHASE2RECRUITING
Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and Placebo PHASE2COMPLETED
Lovaza's Effect on the Activation of Platelets PHASE2COMPLETED
Cholic Acid for Hepatic Steatosis in Lipodystrophy PHASE2COMPLETED
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides PHASE1COMPLETED
Choline Effects - Pre-symptomatic AD PHASE1COMPLETED
Sphingo-lipotoxicity and Trans-differentiation of Adipose Tissue in Obesity (SFINGOTRANS) nanCOMPLETED
Enpowering Progression Risk of Cerebral Amyloid Angiopathy nanCOMPLETED
Lipidomic and Multi-Omics Profiling of Fatty Liver Disease in People With and Without HIV nanNOT_YET_RECRUITING
Studying Lipids as Potential Biomarkers in Patients With Fabry Disease nanCOMPLETED
Registry Gangliosidoses nanUNKNOWN
A Study Measuring Substances Potentially Indicating Bone Problems in Adults With Type 1 Gaucher Condition nanCOMPLETED
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia nanUNKNOWN
Structural Network on Prostate Cancer in the French Greater West Region nanCOMPLETED
Postprandial Lipotoxicity and Nonalcoholic Fatty Liver Disease nanCOMPLETED
Free Fatty Acid Induced Insulin Resistance nanCOMPLETED
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease nanCOMPLETED
Biochemical and Phenotypical Aspects of Smith-Lemli-Opitz Syndrome and Related Disorders of Cholesterol Metabolism nanRECRUITING
Effect of Plasma Ceramides on Peripheral Vascular Function nanCOMPLETED
Duality of Lipids: the Athlete's Paradox nanCOMPLETED
Evaluation of Serum Ceramides C16, C24, and Sphingosine-1-Phosphate (S1P) in Patients With Acne Vulgaris nanNOT_YET_RECRUITING
Plasma Dihydroceramides Are Associated With Hepatic Steatosis in Type 1 and Type 2 Diabetes nanCOMPLETED
Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on Insulin Resistance in Humans nanCOMPLETED
Serum FFA Desaturase Activity Index in Patients on High Dose Corticosteroids nanUNKNOWN
The LD Lync Study - Natural History Study of Lipodystrophy Syndromes nanRECRUITING
Genetic Determinants:Low HDL, High Triglycerides, Obesity nanCOMPLETED
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2) nanWITHDRAWN

Related proteins — ESM-2 sequence neighbours (a DEGS1 binder may also engage these)

ProteinNameSimilarity
Q5RE51 — 1.000 Q5RE51 →
Q5F3C1 — 1.000 Q5F3C1 →
Q5XIF5 — 1.000 Q5XIF5 →
Q3ZBY7 — 1.000 Q3ZBY7 →
Q6UQ04 — 1.000 Q6UQ04 →
Q68FB8 — 1.000 Q68FB8 →
O09005 — 0.999 O09005 →
Q94515 — 0.996 Q94515 →
Q564G3 — 0.992 Q564G3 →
Q8R2F2 — 0.990 Q8R2F2 →
P46313 — 0.985 P46313 →
Q6H5U3 — 0.983 Q6H5U3 →
Q39287 — 0.980 Q39287 →
Q0II71 — 0.980 Q0II71 →
Q9SCG2 — 0.978 Q9SCG2 →
Q84UB9 — 0.978 Q84UB9 →
Q8GZC2 — 0.977 Q8GZC2 →
Q9AT72 — 0.977 Q9AT72 →
Q41131 — 0.977 Q41131 →
Q6RS95 — 0.974 Q6RS95 →
P48630 — 0.971 P48630 →
Q9ZPH4 — 0.971 Q9ZPH4 →
Q9LND9 — 0.968 Q9LND9 →
A3F5L3 — 0.966 A3F5L3 →
Q6QHC5 — 0.966 Q6QHC5 →
Q9LND8 — 0.965 Q9LND8 →
Q9FPD5 — 0.965 Q9FPD5 →
Q84UB8 — 0.964 Q84UB8 →
Q9SUC5 — 0.963 Q9SUC5 →
O81931 — 0.962 O81931 →